clinical trial · NCT03772678
A Phase I Study to Evaluate LSALT Peptide
None - Study is to Determine Safety in Healthy ParticipantsLSALT peptide0.9% Saline
brief summary
A phase I double-blind, placebo-controlled, randomized, single and multiple ascending dose finding study to evaluate the safety and pharmacokinetic profile of LSALT peptide in healthy participants
started
Jun 27, 2019
primary completion
Mar 31, 2020
completion
Mar 31, 2020
last updated
Nov 29, 2024
official title
A Phase I Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Finding Study to Evaluate the Safety and Pharmacokinetic Profile of LSALT Peptide in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol